BERLIN--(BUSINESS WIRE)--ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company developing orally-administered therapeutics that target the chemokine and chemoattractant systems, today announced positive data from the company’s Phase 2 clinical trial of Traficet-EN® (CCX282-B) for the treatment of Crohn’s disease at the 14th United European Gastroenterology Week (UEGW 2006) meeting in Berlin, Germany. Traficet-EN® is a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9.
